Allscripts (MDRX) Initiates Cost Restructuring - Canaccord Genuity

September 17, 2021 8:35 AM EDT
Get Alerts MDRX Hot Sheet
Price: $13.59 -1.52%

Rating Summary:
    7 Buy, 21 Hold, 3 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 14 | New: 48
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

Canaccord Genuity analyst Richard Close reiterated a Buy rating and $18.00 price target on Allscripts (NASDAQ: MDRX) after the company initiated efforts to streamline its business through cost restructuring and a focus on driving improved value creation for shareholders has led to improved margins and share performance over the last 1 1/2 years.

The analyst stated "The successful divestiture of CarePort and EPSi enabled the company to de-lever and actively repurchase shares to drive earnings growth. The company has continued its efforts to drive returns for investors, continuing to repurchase shares and recently selling its 2bPrecise precision medicine business that was internally developed. Mgmt remains focused on cost management and cash flow conversion evidenced by raising adj-EBITDA and free cash flow guidance with its 2Q'21 report. A return to revenue growth will be the catalyst to get shares to rise meaningfully from current levels; however, we still believe that shares still offer value to investors. Our $18 PT implies ~30% upside from current levels and is based on 10.3x (27.5% discount to peer group) our 2022E adj-EBITDA

For an analyst ratings summary and ratings history on Allscripts click here. For more ratings news on Allscripts click here.

Shares of Allscripts closed at $13.78 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments

Related Entities

Earnings, Canaccord Genuity